<DOC>
	<DOC>NCT00743964</DOC>
	<brief_summary>Recently, 3-drug (ECX) and 2-drug (CX) combination chemotherapy involving capecitabine showed promising results in randomized clinical trials for advanced gastric cancer (AGC). The objective of the study is to evaluate the safety and activity of ECX and CX combination chemotherapy given as first-line therapy for AGC.</brief_summary>
	<brief_title>Phase II Study of Epirubicin, Cisplatin and Capecitabine (ECX) Versus Cisplatin and Capecitabine (CX) for Advanced Gastric Cancer (AGC)</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>Aged 75 years or less Adenocarcinoma of stomach Advanced, metastatic, or recurrent No prio chemotherapy for advanced disease Adequate performance status Adequate major organ functions Severe comorbid illness or active infections Pregnancy or lactating women GI obstruction or malabsorption syndrome</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2010</verification_date>
</DOC>